Longboard Pharmaceuticals (LBPH) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[2], including 3 Phase 3[1].
Trial NCT06660394[3] evaluates LP352 in Dravet Syndrome with a target enrollment of 160 participants. Trial NCT06908226[4] evaluates LP352 in Developmental and Epileptic Encephalopathy with a target enrollment of 324 participants. Trial NCT06719141[5] evaluates LP352 in Developmental and Epileptic Encephalopathy with a target enrollment of 320 participants.
No Form 4 insider filings for LBPH were recorded at the SEC in the past 30 days[6].